Bexarotene, Free Acid (Targretin, Targretyn, Targrexin, LGD-1069, LG 1069, LG100069, D03106, SR-11247, DB00307, 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid, CAS 153559-49-0), >99%

LC Laboratories' Product Number B-2422 - Bexarotene, Free Acid (Targretin, Targretyn, Targrexin, LGD-1069, LG 1069, LG100069, D03106, SR-11247, DB00307, 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid, CAS 153559-49-0), >99% - for research use only. Bexarotene (LGD-1069) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. It is an oral, noncytotoxic drug that was approved in Europe and in the U.S.A. for the treatment of refractory advanced-stage cutaneous T-cell lymphomas (CTCL). Compared with historical results with combination chemotherapy alone, bexarotene in combination with chemotherapeutic agents has showed an encouraging median survival for patients with advanced non-small cell lung cancer. The receptor-selective retinoids might be particularly useful in preventing ER-negative breast cancer. Results from cell culture treatments and in vivo xenograft models suggested that bexarotene in combination with chemotherapeutic agents might play an important role in preventing and overcoming acquired drug resistance in advanced prostate cancer, breast carcinoma, and non-small cell lung cancer. Bexarotene is the active ingredient in the drug sold under the trade name Targretin®, which has been approved in at least one country for treatment of patients with CTCL.

• Supplier: LC Laboratories
• Product #: B-2422
• Sku #: B-2422_1g